GlassScriptPhysician profile
Mher Onanyan
NPI 1861755241
$8,265.43
in general payments reported to CMS, 2019-2025
21 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $174 · 2021: $128 · 2022: $407 · 2023: $6,549 · 2024: $383 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $876 · Travel and Lodging: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $875.70 |
| Travel and Lodging | $305.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,520.18 | 2023-2024 | Da Vinci Surgical System, Ion |
| Boehringer Ingelheim Pharmaceuticals, INC. | $497.59 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $222.03 | 2020-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $200.47 | 2019 | |
| Inari Medical, INC. | $165.77 | 2022 | |
| Glaxosmithkline, LLC. | $122.36 | 2019-2022 | |
| Electromed, INC. | $111.19 | 2019-2021 | |
| Novo Nordisk INC | $90.65 | 2022 | |
| Merck Sharp & Dohme LLC | $58.56 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $37.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.58 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.75 | 2024 | Lifevest |
| Astellas Pharma US INC | $28.00 | 2019 | |
| Daiichi Sankyo INC. | $22.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.09 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $20.00 | 2024 | |
| Lilly USA, LLC | $19.75 | 2020 | |
| Csl Behring | $15.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.20 | 2019 | |
| Amgen INC. | $13.56 | 2020 | |
| Allergan, INC. | $12.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mher Onanyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.